The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Amid the firestorm of blame about drug prices, a new report has just made one thing clear: pharmaceutical companies are dependent on them for growth.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year, according to a report published this week by Credit Suisse, which called pricing "the most important issue for a pharma investor today."
The increases came despite heightened public scrutiny for the drug industry throughout the U.S.presidential election.
The companies most dependent on price increases for growth, per the Credit Suisse report: Biogen, Eli Lilly and AbbVie, for which U.S. net price growth accounted for more than 100 percent of total net income growth last year. That means without price increases, earnings would have declined.
And amid continued pressure—President Donald Trump said in January that the pharmaceutical industry was "getting away with murder" in its pricing practices—the increases continued in the first quarter of this year, a separate report from Cowen shows. There were 40 increases on drug prices in the first quarter of 2017, up from 33 in 2016.